<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908800</url>
  </required_header>
  <id_info>
    <org_study_id>KRPA218-T101</org_study_id>
    <nct_id>NCT04908800</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects</brief_title>
  <official_title>A First-in-Human, Phase I, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects, Including Food-Effect and Drug-drug Interaction With Itraconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyorin Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyorin Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study has three parts. In Parts A and B, the safety, tolerability, and&#xD;
      pharmacokinetics (PK) will be evaluated following administration of single and multiple doses&#xD;
      of KRP-A218, including food-effect. In Part C, the drug-drug interaction (DDI) with&#xD;
      itraconazole will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">March 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of participants with adverse events</measure>
    <time_frame>Screening to follow-up (Approximately 6 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of participants with adverse events</measure>
    <time_frame>Screening to follow-up (Approximately 8 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Area under concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Area under curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Maximum observed concentration (Cmax)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Time of the maximum observed concentration (tmax)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Apparent total clearance (CL/F)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Apparent volume of distribution during the terminal phase (Vz/F)</measure>
    <time_frame>Days 1 to 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Area under concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Area under curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Maximum observed concentration (Cmax)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Time of the maximum observed concentration (tmax)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent total clearance (CL/F)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent volume of distribution during the terminal phase (Vz/F)</measure>
    <time_frame>Days 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Area under the concentration-time curve over a dosing interval (AUC0-τ)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Area under concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Area under curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Maximum observed concentration (Cmax)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Minimum observed concentration (Cmin)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Time of the maximum observed concentration (tmax)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent total clearance (CL/F)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent volume of distribution during the terminal phase (Vz/F)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Observed accumulation ratio based on AUC0-τ (ARAUC0-τ)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Observed accumulation ratio based on Cmax during the dosing interval (ARCmax)</measure>
    <time_frame>Days 1 to 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Number of participants with adverse events</measure>
    <time_frame>Screening to follow-up (Approximately 7 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A single ascending dose (SAD) and Part B multiple ascending dose (MAD): KRP-A218</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration Route: Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD) and Part B (MAD): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration Route: Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C drug-drug interaction (DDI): KRP-A218 and itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration Route: Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRP-A218</intervention_name>
    <description>KRP-A218 tablet</description>
    <arm_group_label>Part A single ascending dose (SAD) and Part B multiple ascending dose (MAD): KRP-A218</arm_group_label>
    <arm_group_label>Part C drug-drug interaction (DDI): KRP-A218 and itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Part A (SAD) and Part B (MAD): Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>10 mg/mL oral solution</description>
    <arm_group_label>Part C drug-drug interaction (DDI): KRP-A218 and itraconazole</arm_group_label>
    <other_name>Sporanox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults, between 20 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Body weight ≥50 kg, with body mass index (BMI) between 18.0 and 30.0 kg/m^2,&#xD;
             inclusive.&#xD;
&#xD;
          -  In good health, at Screening or Day -1 as assessed by the Investigator.&#xD;
&#xD;
          -  Females will not be pregnant or lactating, and females of childbearing potential will&#xD;
             agree to use contraception and to not donate eggs (ova, oocytes). Males will agree to&#xD;
             use contraception and to not donate sperm.&#xD;
&#xD;
          -  Able to comprehend and willing to sign an informed consent form (ICF) and to abide by&#xD;
             the study restrictions.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 90 days prior to dosing.&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to dosing.&#xD;
&#xD;
          -  Use or intend to use any prescription medications/products within 14 days or 5&#xD;
             half-lives (whichever is longer) prior to dosing, unless deemed acceptable by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Use or intend to use slow release medications/products considered to still be active&#xD;
             within 14 days prior to dosing, unless deemed acceptable by the Investigator.&#xD;
&#xD;
          -  Use or intend to use any nonprescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior&#xD;
             to dosing, unless deemed acceptable by the Investigator.&#xD;
&#xD;
          -  Use of tobacco or nicotine-containing products within 3 months prior to Day -1, or&#xD;
             positive cotinine test at screening or Day -1.&#xD;
&#xD;
          -  Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages&#xD;
             within 7 days prior to Day -1.&#xD;
&#xD;
          -  Consumption of caffeine- or xanthine-containing foods and beverages within 36 hours&#xD;
             prior to Day -1.&#xD;
&#xD;
          -  Participation in strenuous exercised within 7 days prior to Day -1.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Day -1.&#xD;
&#xD;
          -  Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to&#xD;
             screening, or platelets from 6 weeks prior to screening.&#xD;
&#xD;
          -  Poor peripheral venous access.&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or have previously received the&#xD;
             investigational medicinal product (IMP).&#xD;
&#xD;
          -  Subject is, in the opinion of the Investigator, unlikely to comply with the protocol&#xD;
             or unsuitable to participate in this study for any reason.&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoji Mimaki</last_name>
    <role>Study Chair</role>
    <affiliation>Kyorin Pharmaceutical Co.,Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoji Mimaki</last_name>
    <phone>+81-3-3525-4788</phone>
    <email>ml-kyorin_clinicaltrials.gov@mb.kyorin-pharm.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labcorp Clinical Research</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jim Bush, MB ChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

